Online inquiry

IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6898MR)

This product GTTS-WQ6898MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CX3CL1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_002996.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6376
UniProt ID P78423
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6898MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4946MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ12292MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ2347MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ9015MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ12244MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ9573MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ5387MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ9431MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IPH-2201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW